Doximity (DOCS) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Doximity (NASDAQ: DOCS) in the last few weeks:

• 1/20/2026 – Doximity was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $55.00 price target on the stock, down previously from $65.00.
• 1/9/2026 – Doximity was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $49.00 price target on the stock.
• 1/8/2026 – Doximity is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $59.00 price target on the stock.
• 1/8/2026 – Doximity was given a new $62.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Doximity had its price target lowered by analysts at KeyCorp from $75.00 to $60.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Doximity was given a new $48.00 price target on by analysts at Canaccord Genuity Group Inc..
• 1/8/2026 – Doximity had its “outperform” rating reaffirmed by analysts at Evercore ISI.
• 1/8/2026 – Doximity was upgraded by analysts at Truist Financial Corporation from a “hold” rating to a “buy” rating.
• 12/29/2025 – Doximity had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
• 12/15/2025 – Doximity was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $65.00 price target on the stock, up previously from $62.00.
• 12/8/2025 – Doximity is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $63.00 price target on the stock.
• 12/8/2025 – Doximity is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $63.00 price target on the stock.

Insider Buying and Selling at Doximity

In other news, Director Kira Scherer Wampler sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $66.44, for a total value of $132,880.00. Following the sale, the director owned 19,839 shares of the company’s stock, valued at $1,318,103.16. The trade was a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 31.30% of the stock is owned by insiders.

Doximity, Inc, headquartered in San Francisco, California, operates the leading professional medical network for healthcare professionals in the United States. Founded in 2011 by Jeff Tangney and Shari Buck, the company set out to create a secure digital environment where physicians, nurse practitioners and physician assistants can collaborate, share information and stay current with clinical news. Doximity went public in June 2021 and trades on the NASDAQ under the ticker symbol “DOCS.”

The core offering of Doximity is its HIPAA-compliant communication platform, which includes a secure messaging system, digital fax services and telehealth capabilities.